Immune Thrombocytopenic Purpura

Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

NCT00168038 | PHASE 3 | INTERVENTIONAL

The purpose of this study is to evaluate the efficacy, tolerability and safety of IgPro10 in the treatment of patients with chronic immune thrombocytopenic purpura (ITP). The main efficacy parameter is the proportion of patients responding to treatment by an increase of platelet count to ≥ 50 x 10\^9/L.

17 Sites

58 Participants

Recruiting

12 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study Site

Berlin,Germany

Study Site

Rome,Italy

Study Site

Bialystok,Poland

Study Site

Gdansk,Poland

Study Site

Lodz,Poland

Study Site

Poznan,Poland

Study Site

Warsaw,Poland

Study Site

Wroclaw,Poland

Study Site

Moscow,Russian Federation

Study Site ()

St. Petersburg,Russian Federation

Study Site ()

St. Petersburg,Russian Federation

Study Site ()

St. Petersburg,Russian Federation

Study Site

Dnipropetrovsk,Ukraine

Study Site ()

Kyiv,Ukraine

Study Site ()

Kyiv,Ukraine

Study Site

Lviv,Ukraine

Study Site

Taunton,United Kingdom

Study Eligibility Criteria

Inclusion Criteria

* Diagnosis of chronic ITP defined by: Failure to find other causes of thrombocytopenia; Platelet count ≤ 150 x 10\^9/L over 6 months or response to a previous treatment with subsequent decrease in platelet count even if duration of chronic ITP is less than 6 months
* Platelet counts ≤ 20 x 10\^9/L
Key

Exclusion Criteria

* Planned splenectomy throughout the study period
* Treatment with IVIG or anti-D immunoglobulin within 3 weeks prior to screening
* Treatment with immunosuppressive or other immunomodulatory drugs within 3 weeks prior to screening
* Treatment with intravenous steroids within 10 days prior to screening
* Change of oral steroid treatment within 15 days prior to screening
* Patients with known or suspected hypersensitivity to immunoglobulins or previous severe side effects to immunoglobulin therapy
* Abnormal results in the following laboratory parameters: Hemoglobin \< 10 g/dL; Total bilirubin \> 1.5 x upper normal limit; ALAT \> 2.5 x upper normal limit; ASAT \> 2.5 x upper normal limit; Creatinine \> 1.5 x upper normal limit; Urea \> 1.5 x upper normal limit
* Positive direct Coombs test
* Patients with one of the following concomitant diseases Clinical active SLE Known or suspected HIV infection Acute hepatitis Clinically active chronic hepatitis Lymphoproliferative disease Heart failure Grade III or IV according to the New York Heart Association classification
* Any other concomitant disease that has influence on the clotting system (i.e. hemophilia)

Additional Studies

Additional studies can be found at ClinicalTrials.gov